JPWO2023158668A5 - - Google Patents

Info

Publication number
JPWO2023158668A5
JPWO2023158668A5 JP2024548386A JP2024548386A JPWO2023158668A5 JP WO2023158668 A5 JPWO2023158668 A5 JP WO2023158668A5 JP 2024548386 A JP2024548386 A JP 2024548386A JP 2024548386 A JP2024548386 A JP 2024548386A JP WO2023158668 A5 JPWO2023158668 A5 JP WO2023158668A5
Authority
JP
Japan
Prior art keywords
treatment
compound
antidepressant
optionally
inclusive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024548386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508406A5 (https=
JP2025508406A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/013098 external-priority patent/WO2023158668A1/en
Publication of JP2025508406A publication Critical patent/JP2025508406A/ja
Publication of JP2025508406A5 publication Critical patent/JP2025508406A5/ja
Publication of JPWO2023158668A5 publication Critical patent/JPWO2023158668A5/ja
Pending legal-status Critical Current

Links

JP2024548386A 2022-02-16 2023-02-15 Cns関連障害を処置するための神経活性ステロイド Pending JP2025508406A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263310581P 2022-02-16 2022-02-16
US63/310,581 2022-02-16
US202263337828P 2022-05-03 2022-05-03
US63/337,828 2022-05-03
US202363482200P 2023-01-30 2023-01-30
US63/482,200 2023-01-30
PCT/US2023/013098 WO2023158668A1 (en) 2022-02-16 2023-02-15 Neuroactive steroids for treatment of cns-related disorders

Publications (3)

Publication Number Publication Date
JP2025508406A JP2025508406A (ja) 2025-03-26
JP2025508406A5 JP2025508406A5 (https=) 2026-02-25
JPWO2023158668A5 true JPWO2023158668A5 (https=) 2026-02-25

Family

ID=85569830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024548386A Pending JP2025508406A (ja) 2022-02-16 2023-02-15 Cns関連障害を処置するための神経活性ステロイド

Country Status (11)

Country Link
US (1) US20250295674A1 (https=)
EP (1) EP4479032A1 (https=)
JP (1) JP2025508406A (https=)
KR (1) KR20240148425A (https=)
CN (1) CN119072304A (https=)
AU (1) AU2023220976A1 (https=)
CA (1) CA3252357A1 (https=)
IL (1) IL315023A (https=)
MX (1) MX2024009974A (https=)
TW (1) TW202341995A (https=)
WO (1) WO2023158668A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
AU2022266680A1 (en) * 2021-04-29 2023-11-02 Sage Therapeutics, LLC 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
CN117442618B (zh) * 2023-10-23 2025-11-14 国科大杭州高等研究院 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
US20230285417A1 (en) 2020-07-20 2023-09-14 Sage Therapeutics, Inc. Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Similar Documents

Publication Publication Date Title
EP3833343B1 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
KR100720290B1 (ko) 부프로피온 대사물, 이들의 합성방법 및 사용방법
US20090306137A1 (en) Treatment for depressive disorders
JP2009511618A (ja) 中度から重度のむずむず脚症候群(rls)を治療するためのプラミペキソールの使用
JP2008538741A (ja) 鬱病の治療用及び/又は予防用の医薬組成物
JP2006143749A (ja) 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法
JPH08208471A (ja) 薬物反応の増強作用
JP2008531714A (ja) 不安障害の治療用及び/又は予防用の医薬組成物
JPWO2023158668A5 (https=)
PT1628652E (pt) Combinação do modafinil analéptico e um antidepressivo para o tratamento da depressão
AU2002348266A1 (en) Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
US20040229940A1 (en) Analeptic and antidepressant combinations
WO2004100940A1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
AU2002239572B2 (en) Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
CN1197569C (zh) 神经病症的新疗法
SK3272001A3 (en) A new composition
AU2002239572A1 (en) Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines
EP1928448B1 (fr) ASSOCIATION D'AGONISTE AUX RECEPTEURS ß3 ET D'INHIBITEURS DE LA RECAPTURE DE MONOAMINES, COMPOSITION PHARMACEUTIQUE LA CONTENANT ET SON UTILISATION EN THERAPEUTIQUE
AU6377999A (en) A new composition
HK1100481A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of sleep disorders in the depressed patient
JPWO2023118123A5 (https=)
AU2008200875A1 (en) Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines